source
- Merck licenses KRAS G12D inhibitor from Tao Hu for $400 million upfrontMerck has signed a licensing agreement for a KRAS G12D inhibitor, providing an upfront payment of $400 million. The deal follows a 2023 transaction in which the same entrepreneur, synthetic chemis…
- Roche halts obesity antibody emugrobart after negative phase 2 interim readoutRoche has stopped development of its obesity antibody emugrobart after an interim analysis of a phase 2 trial indicated a low chance of meeting the study endpoints. The antibody, designed to block…